ATE457364T1 - Verwendung neuer hnf4alpha-zielgene und ihrer genprodukte - Google Patents
Verwendung neuer hnf4alpha-zielgene und ihrer genprodukteInfo
- Publication number
- ATE457364T1 ATE457364T1 AT06724120T AT06724120T ATE457364T1 AT E457364 T1 ATE457364 T1 AT E457364T1 AT 06724120 T AT06724120 T AT 06724120T AT 06724120 T AT06724120 T AT 06724120T AT E457364 T1 ATE457364 T1 AT E457364T1
- Authority
- AT
- Austria
- Prior art keywords
- genes
- tprc1
- hnf4
- channel
- pak5
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 14
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 abstract 8
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 abstract 7
- 206010012601 diabetes mellitus Diseases 0.000 abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 101001051723 Homo sapiens Ribosomal protein S6 kinase alpha-6 Proteins 0.000 abstract 4
- 101000987295 Homo sapiens Serine/threonine-protein kinase PAK 5 Proteins 0.000 abstract 4
- 101000983111 Homo sapiens Serine/threonine-protein kinase PAK 6 Proteins 0.000 abstract 4
- 102100026840 Serine/threonine-protein kinase PAK 6 Human genes 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 4
- 108091006146 Channels Proteins 0.000 abstract 3
- 101710163587 Epidermal growth factor receptor substrate 15-like 1 Proteins 0.000 abstract 3
- 102100024897 Ribosomal protein S6 kinase alpha-6 Human genes 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 208000030159 metabolic disease Diseases 0.000 abstract 3
- 102100030390 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 Human genes 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 2
- 102100030778 Epidermal growth factor receptor substrate 15-like 1 Human genes 0.000 abstract 2
- 101000583063 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 Proteins 0.000 abstract 2
- 101000994648 Homo sapiens Potassium voltage-gated channel subfamily KQT member 4 Proteins 0.000 abstract 2
- 102100034363 Potassium voltage-gated channel subfamily KQT member 4 Human genes 0.000 abstract 2
- 238000010171 animal model Methods 0.000 abstract 2
- 230000033228 biological regulation Effects 0.000 abstract 2
- 239000011575 calcium Substances 0.000 abstract 2
- 229910052791 calcium Inorganic materials 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 210000000496 pancreas Anatomy 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 230000004614 tumor growth Effects 0.000 abstract 2
- 102100024378 AF4/FMR2 family member 2 Human genes 0.000 abstract 1
- 108091005462 Cation channels Proteins 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 101000833172 Homo sapiens AF4/FMR2 family member 2 Proteins 0.000 abstract 1
- 101000588157 Homo sapiens Microtubule-associated tumor suppressor candidate 2 Proteins 0.000 abstract 1
- 101000588345 Homo sapiens Nuclear transcription factor Y subunit gamma Proteins 0.000 abstract 1
- 101100256027 Homo sapiens SLC35B1 gene Proteins 0.000 abstract 1
- 101000674603 Homo sapiens Threonine aspartase 1 Proteins 0.000 abstract 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 108090000862 Ion Channels Proteins 0.000 abstract 1
- 102000004310 Ion Channels Human genes 0.000 abstract 1
- 102100031549 Microtubule-associated tumor suppressor candidate 2 Human genes 0.000 abstract 1
- -1 NEB Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100031719 Nuclear transcription factor Y subunit gamma Human genes 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 102100025664 Solute carrier family 35 member B1 Human genes 0.000 abstract 1
- 102000003627 TRPC1 Human genes 0.000 abstract 1
- 101150017559 TRPC1 gene Proteins 0.000 abstract 1
- 102100040483 Threonine aspartase 1 Human genes 0.000 abstract 1
- 108091023040 Transcription factor Proteins 0.000 abstract 1
- 102000040945 Transcription factor Human genes 0.000 abstract 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 abstract 1
- 230000008827 biological function Effects 0.000 abstract 1
- 229940032955 calcium homeostasis Drugs 0.000 abstract 1
- 230000004094 calcium homeostasis Effects 0.000 abstract 1
- 230000022131 cell cycle Effects 0.000 abstract 1
- 210000003477 cochlea Anatomy 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 210000002768 hair cell Anatomy 0.000 abstract 1
- 208000016354 hearing loss disease Diseases 0.000 abstract 1
- 230000004941 influx Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108700013540 rat Wwc1 Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000022983 regulation of cell cycle Effects 0.000 abstract 1
- 230000016515 regulation of signal transduction Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000001953 sensory effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05090108A EP1712641A1 (de) | 2005-04-14 | 2005-04-14 | Verwendung von neuen HNF4a Zielgenen und ihren Produkten |
| PCT/EP2006/003179 WO2006125493A2 (en) | 2005-04-14 | 2006-04-07 | USE OF NOVEL HNF4α TARGET GENES AND THEIR GENE PRODUCTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE457364T1 true ATE457364T1 (de) | 2010-02-15 |
Family
ID=35887847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06724120T ATE457364T1 (de) | 2005-04-14 | 2006-04-07 | Verwendung neuer hnf4alpha-zielgene und ihrer genprodukte |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090036348A1 (de) |
| EP (2) | EP1712641A1 (de) |
| AT (1) | ATE457364T1 (de) |
| DE (1) | DE602006012173D1 (de) |
| WO (1) | WO2006125493A2 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4165194A2 (de) * | 2020-05-13 | 2023-04-19 | Akouos, Inc. | Zusammensetzungen und verfahren zur behandlung von kcnq4-assoziiertem gehörverlust |
| CN114425090B (zh) * | 2022-01-26 | 2024-01-26 | 四川大学华西医院 | Xrcc6基因及其编码的蛋白的应用 |
| CN115028705A (zh) * | 2022-05-09 | 2022-09-09 | 常熟理工学院 | Hnf6多肽片段及其表达与纯化方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998023780A1 (en) * | 1996-11-26 | 1998-06-04 | Joslin Diabetes Center, Inc. | Methods for diagnosing and treating diabetes |
| WO2003016559A2 (en) * | 2001-08-17 | 2003-02-27 | Novo Nordisk A/S | Method for treating diabetes based on the modulation of nh4alpha gene expression |
-
2005
- 2005-04-14 EP EP05090108A patent/EP1712641A1/de not_active Withdrawn
-
2006
- 2006-04-07 AT AT06724120T patent/ATE457364T1/de not_active IP Right Cessation
- 2006-04-07 US US11/918,156 patent/US20090036348A1/en not_active Abandoned
- 2006-04-07 WO PCT/EP2006/003179 patent/WO2006125493A2/en not_active Ceased
- 2006-04-07 DE DE602006012173T patent/DE602006012173D1/de not_active Expired - Lifetime
- 2006-04-07 EP EP06724120A patent/EP1871900B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006125493A2 (en) | 2006-11-30 |
| US20090036348A1 (en) | 2009-02-05 |
| EP1871900A2 (de) | 2008-01-02 |
| EP1712641A1 (de) | 2006-10-18 |
| WO2006125493A3 (en) | 2007-06-28 |
| DE602006012173D1 (de) | 2010-03-25 |
| EP1871900B1 (de) | 2010-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Padmanabhan et al. | Frontotemporal dementia mutant Tau promotes aberrant Fyn nanoclustering in hippocampal dendritic spines | |
| Del Amo et al. | Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2 | |
| Baratchi et al. | Secreted amyloid precursor proteins promote proliferation and glial differentiation of adult hippocampal neural progenitor cells | |
| Larhammar et al. | SLC10A4 is a vesicular amine-associated transporter modulating dopamine homeostasis | |
| MX2007004551A (es) | Compuestos tiadiazol y metodos de uso. | |
| Smith et al. | Astrocyte deletion of α2-Na/K ATPase triggers episodic motor paralysis in mice via a metabolic pathway | |
| EA200501667A1 (ru) | Рецепторный комплекс тканезащитных цитокинов, способы идентификации тканезащитных соединений и их применение | |
| Hirokawa et al. | Regulation of axonal regeneration by the level of function of the endogenous Nogo receptor antagonist LOTUS | |
| Spilman et al. | Netrin-1 interrupts amyloid-β amplification, increases sAβPPα in vitro and in vivo, and improves cognition in a mouse model of Alzheimer’s disease | |
| Wu et al. | Multiple signaling factors and drugs alleviate neuronal death induced by expression of human and zebrafish tau proteins in vivo | |
| Sun et al. | Nerve bundle formation during the promotion of peripheral nerve regeneration: collagen VI-neural cell adhesion molecule 1 interaction | |
| CN102439041A (zh) | 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节 | |
| Gebril et al. | Adenosine kinase inhibition promotes proliferation of neural stem cells after traumatic brain injury | |
| Tian et al. | Immunoreactivity of 43ákDa growth-associated protein is decreased in post mortem hippocampus of bipolar disorder and schizophrenia | |
| Granholm | Oestrogen and nerve growth factor–neuroprotection and repair in Alzheimer’s disease | |
| Joffe et al. | Frontal cortex genetic ablation of metabotropic glutamate receptor subtype 3 (mGlu3) impairs postsynaptic plasticity and modulates affective behaviors | |
| Canals et al. | Astrocyte dysfunction and neuronal network hyperactivity in a CRISPR engineered pluripotent stem cell model of frontotemporal dementia | |
| Lee et al. | mtIF3 is locally translated in axons and regulates mitochondrial translation for axonal growth | |
| Thomasen et al. | SorCS2 binds progranulin to regulate motor neuron development | |
| DE602006012173D1 (de) | Verwendung neuer hnf4alpha-zielgene und ihrer genprodukte | |
| Matthews et al. | UBQLN2 in neurodegenerative disease: mechanistic insights and emerging therapeutic potential | |
| Wang et al. | The interleukin-1-related cytokine IL-1F8 is expressed in glial cells, but fails to induce IL-1β signalling responses | |
| Cao et al. | Cadherin 11 regulates presynaptic vesicle trafficking and neuronal activity in autism-related brain circuit | |
| Wang et al. | Loss of the parkinsonism‐associated protein FBXO7 in glutamatergic forebrain neurons in mice leads to abnormal motor behavior and synaptic defects | |
| WO2005017102A3 (en) | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |